Dr. John Thoppil, Current President of the Texas Association of Obstetricians and Gynecologists (TAOG), Performs Sonata Procedure in Austin
Redwood City, CA, October 5, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Dr. John Thoppil is the first physician in the state of Texas to offer its Sonata® Treatment to women with symptomatic uterine fibroids as an office-based procedure at his River Place OB/GYN facility in Austin.
“I am excited to offer this transcervical option for fibroid treatment in an office setting. Sonata is brilliant in concept; it reduces symptoms without any incisions at all,” said John Thoppil, MD, FACOG and President of TAOG. “We are honored to be the first medical group to offer Sonata in-office, in the state of Texas. In addition to the office, we will be offering the procedure in the traditional outpatient surgical center setting. The ability to utilize multiple sites of service, with no incisions and a rapid recovery, is one of the most important recent treatment advances for women with symptomatic fibroids and their physicians, not only in Texas, but across the globe.”
The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wider range of fibroid types, sizes, and locations than hysteroscopic myomectomy. Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained.
“We are incredibly fortunate to have advocates like Dr. Thoppil, who are able to quickly utilize the advantages unique to the Sonata Transcervical Fibroid Ablation (TFA) Procedure,” said Chris Owens, President and CEO of Gynesonics. “The recent guidelines released by the American College of Obstetricians and Gynecologists (ACOG) recognized TFA as an important fibroid treatment that can be offered to women. Sonata is the only fibroid ablation system that does not require incisions or abdominal surgery. Sonata has been uniquely designed to help patients gain access to care through multiple sites of service, supporting rapid adoption around the globe.”
For more information on the Sonata System, go to www.gynesonics.com.
About Sonata System
The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer. The System includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment. The Sonata System provides incision-free transcervical access for a uterus-preserving fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. Most side effects are typically minor and temporary. The
Sonata System is CE marked and is approved for sale in the European Union, the United Kingdom, and the United States.
Fibroids are benign growths in or around the uterus. They are common and most women develop them during childbearing age. In the U.S., around 70% of white women and more than 80% of black women will have uterine fibroids before the age of 50. Problematic fibroids can range in size from a raisin to a grapefruit, and symptoms may worsen over time if fibroids are left untreated. 20% to 50% of women with fibroids are symptomatic and each year in the U.S., more than 2 million women undergo treatment for uterine fibroids. Women with symptomatic fibroids may present one or more of the following:
· Abnormal uterine bleeding/menorrhagia
· Abdominopelvic pain/pressure
· Increased abdominal girth
· Urinary frequency
· Pregnancy complications
· Dyspareunia (painful intercourse)
Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Gynesonics headquarters is in Redwood City, CA. For more information, go to www.gynesonics.com.
Company Contact: Stan Van Gent, Senior Director, Global Marketing, Gynesonics, email@example.com, (661) 388-6380
Media Contact: David Gutierrez, Dresner Corporate Services, firstname.lastname@example.org, (312) 780-7204